These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 19389393)

  • 21. Silodosin, a new alpha1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men.
    Kawabe K; Yoshida M; Homma Y;
    BJU Int; 2006 Nov; 98(5):1019-24. PubMed ID: 16945121
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe.
    Chapple CR; Montorsi F; Tammela TL; Wirth M; Koldewijn E; Fernández Fernández E;
    Eur Urol; 2011 Mar; 59(3):342-52. PubMed ID: 21109344
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An investigation of the uroselective properties of four novel alpha(1a)-adrenergic receptor subtype-selective antagonists.
    Pulito VL; Li X; Varga SS; Mulcahy LS; Clark KS; Halbert SA; Reitz AB; Murray WV; Jolliffe LK
    J Pharmacol Exp Ther; 2000 Jul; 294(1):224-9. PubMed ID: 10871316
    [TBL] [Abstract][Full Text] [Related]  

  • 24. KMD-3213, a uroselective and long-acting alpha(1a)-adrenoceptor antagonist, tested in a novel rat model.
    Akiyama K; Hora M; Tatemichi S; Masuda N; Nakamura S; Yamagishi R; Kitazawa M
    J Pharmacol Exp Ther; 1999 Oct; 291(1):81-91. PubMed ID: 10490890
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Short-term effects of crossover treatment with silodosin and tamsulosin hydrochloride for lower urinary tract symptoms associated with benign prostatic hyperplasia.
    Miyakita H; Yokoyama E; Onodera Y; Utsunomiya T; Tokunaga M; Tojo T; Fujii N; Yanada S
    Int J Urol; 2010 Oct; 17(10):869-75. PubMed ID: 20735791
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of α1-adrenoceptor antagonists on phenylephrine-induced salivary secretion and intraurethral pressure elevation in anesthetized rats.
    Yanai-Inamura H; Ohtake A; Noguchi Y; Hatanaka T; Suzuki M; Ueshima K; Sato S; Sasamata M
    Eur J Pharmacol; 2012 Mar; 679(1-3):127-31. PubMed ID: 22314219
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of silodosin and naftopidil on the distal ureter and cardiovascular system in anesthetized dogs: comparison of potential medications for distal ureteral stone passage.
    Kobayashi S; Tomiyama Y; Hoyano Y; Yamazaki Y; Sasaki S; Kohri K
    J Urol; 2010 Jan; 183(1):357-61. PubMed ID: 19914658
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacological characterization of the uroselective alpha-1 antagonist Rec 15/2739 (SB 216469): role of the alpha-1L adrenoceptor in tissue selectivity, part I.
    Leonardi A; Hieble JP; Guarneri L; Naselsky DP; Poggesi E; Sironi G; Sulpizio AC; Testa R
    J Pharmacol Exp Ther; 1997 Jun; 281(3):1272-83. PubMed ID: 9190863
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of prophylactic naftopidil, tamsulosin, and silodosin for 125I brachytherapy-induced lower urinary tract symptoms in patients with prostate cancer: randomized controlled trial.
    Tsumura H; Satoh T; Ishiyama H; Tabata K; Kotani S; Minamida S; Kimura M; Fujita T; Matsumoto K; Kitano M; Hayakawa K; Baba S
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e385-92. PubMed ID: 21664068
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study.
    Nishino Y; Masue T; Miwa K; Takahashi Y; Ishihara S; Deguchi T
    BJU Int; 2006 Apr; 97(4):747-51, discussion 751. PubMed ID: 16536766
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of selective and nonselective alpha-1-adrenoceptor antagonists on intraurethral and arterial pressures in intact conscious dogs.
    Brune ME; Katwala SP; Milicic I; Buckner SA; Ireland LM; Kerwin JF; Hancock AA
    Pharmacology; 1996 Dec; 53(6):356-68. PubMed ID: 9032800
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Silodosin for the treatment of benign prostatic hyperplasia: pharmacology and cardiovascular tolerability.
    Lepor H; Hill LA
    Pharmacotherapy; 2010 Dec; 30(12):1303-12. PubMed ID: 21114397
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Silodosin for benign prostatic hyperplasia.
    Cantrell MA; Bream-Rouwenhorst HR; Hemerson P; Magera JS
    Ann Pharmacother; 2010 Feb; 44(2):302-10. PubMed ID: 20071497
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized crossover study comparing patient preference for tamsulosin and silodosin in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia.
    Watanabe T; Ozono S; Kageyama S
    J Int Med Res; 2011; 39(1):129-42. PubMed ID: 21672315
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of tamsulosin on resting urethral pressure and arterial blood pressure in anaesthetized female dogs.
    Ohtake A; Sato S; Sasamata M; Miyata K
    J Pharm Pharmacol; 2006 Mar; 58(3):345-50. PubMed ID: 16536901
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Silodosin, a novel selective alpha 1A-adrenoceptor selective antagonist for the treatment of benign prostatic hyperplasia.
    Yoshida M; Homma Y; Kawabe K
    Expert Opin Investig Drugs; 2007 Dec; 16(12):1955-65. PubMed ID: 18042003
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro and in vivo effects of endothelin-1 and YM598, a selective endothelin ET A receptor antagonist, on the lower urinary tract.
    Ukai M; Yuyama H; Fujimori A; Koakutsu A; Sanagi M; Ohtake A; Sato S; Sudoh K; Sasamata M; Miyata K
    Eur J Pharmacol; 2008 Feb; 580(3):394-400. PubMed ID: 18078923
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prediction of alpha1-adrenoceptor occupancy in the human prostate from plasma concentrations of silodosin, tamsulosin and terazosin to treat urinary obstruction in benign prostatic hyperplasia.
    Yamada S; Kato Y; Okura T; Kagawa Y; Kawabe K
    Biol Pharm Bull; 2007 Jul; 30(7):1237-41. PubMed ID: 17603160
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study.
    Roehrborn CG; Siami P; Barkin J; Damião R; Major-Walker K; Morrill B; Montorsi F;
    J Urol; 2008 Feb; 179(2):616-21; discussion 621. PubMed ID: 18082216
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rapid efficacy of the highly selective α(1A)-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies.
    Marks LS; Gittelman MC; Hill LA; Volinn W; Hoel G
    J Urol; 2013 Jan; 189(1 Suppl):S122-8. PubMed ID: 23234617
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.